JP7834025B2 - グルカゴン類縁体の液体製剤 - Google Patents

グルカゴン類縁体の液体製剤

Info

Publication number
JP7834025B2
JP7834025B2 JP2022555741A JP2022555741A JP7834025B2 JP 7834025 B2 JP7834025 B2 JP 7834025B2 JP 2022555741 A JP2022555741 A JP 2022555741A JP 2022555741 A JP2022555741 A JP 2022555741A JP 7834025 B2 JP7834025 B2 JP 7834025B2
Authority
JP
Japan
Prior art keywords
present
concentration
aqueous liquid
hypoglycemia
stable aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022555741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518052A (ja
JP2023518052A5 (https=
Inventor
ビラドセン，イェスパー・スコボー
ゴッツシャルク・ボービング，ティナ・エリザベト
Original Assignee
ジーランド・ファルマ・アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド・ファルマ・アー／エス filed Critical ジーランド・ファルマ・アー／エス
Publication of JP2023518052A publication Critical patent/JP2023518052A/ja
Publication of JP2023518052A5 publication Critical patent/JP2023518052A5/ja
Application granted granted Critical
Publication of JP7834025B2 publication Critical patent/JP7834025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022555741A 2020-03-16 2021-03-16 グルカゴン類縁体の液体製剤 Active JP7834025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20163408.6 2020-03-16
EP20163408 2020-03-16
PCT/EP2021/056651 WO2021185821A1 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues

Publications (3)

Publication Number Publication Date
JP2023518052A JP2023518052A (ja) 2023-04-27
JP2023518052A5 JP2023518052A5 (https=) 2024-03-26
JP7834025B2 true JP7834025B2 (ja) 2026-03-23

Family

ID=70008261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555741A Active JP7834025B2 (ja) 2020-03-16 2021-03-16 グルカゴン類縁体の液体製剤

Country Status (22)

Country Link
US (2) US20210283053A1 (https=)
EP (1) EP4121003B1 (https=)
JP (1) JP7834025B2 (https=)
CN (1) CN115279341B (https=)
AR (1) AR121581A1 (https=)
AU (1) AU2021236878B2 (https=)
BR (1) BR112022018462A2 (https=)
CA (1) CA3171184A1 (https=)
CL (1) CL2022002472A1 (https=)
CO (1) CO2022014452A2 (https=)
ES (1) ES3041327T3 (https=)
HR (1) HRP20251267T1 (https=)
HU (1) HUE073401T2 (https=)
IL (1) IL295977A (https=)
MX (1) MX2022011227A (https=)
PE (1) PE20230258A1 (https=)
PH (1) PH12022552457A1 (https=)
PL (1) PL4121003T3 (https=)
RS (1) RS67245B1 (https=)
TW (1) TW202200190A (https=)
UA (1) UA129439C2 (https=)
WO (1) WO2021185821A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880227B (zh) * 2022-05-30 2025-04-11 丹麥商西蘭製藥公司 澱粉素類似物之液體調配物
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524419A (ja) 2012-07-23 2015-08-24 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2019008033A1 (en) 2017-07-05 2019-01-10 Zealand Pharma A/S METHODS AND MEDICAL USES RELATING TO THE TREATMENT OF HYPOGLYCEMIA
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524419A (ja) 2012-07-23 2015-08-24 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2019008033A1 (en) 2017-07-05 2019-01-10 Zealand Pharma A/S METHODS AND MEDICAL USES RELATING TO THE TREATMENT OF HYPOGLYCEMIA
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Also Published As

Publication number Publication date
NZ791927A (en) 2025-09-26
PE20230258A1 (es) 2023-02-07
CO2022014452A2 (es) 2022-10-21
EP4121003A1 (en) 2023-01-25
PL4121003T3 (pl) 2026-02-23
WO2021185821A1 (en) 2021-09-23
AU2021236878A1 (en) 2022-09-29
CL2022002472A1 (es) 2023-02-17
JP2023518052A (ja) 2023-04-27
ES3041327T3 (en) 2025-11-11
PH12022552457A1 (en) 2023-12-11
TW202200190A (zh) 2022-01-01
EP4121003B1 (en) 2025-08-06
CA3171184A1 (en) 2021-09-23
US20210283053A1 (en) 2021-09-16
HRP20251267T1 (hr) 2025-12-05
BR112022018462A2 (pt) 2022-11-01
IL295977A (en) 2022-10-01
AU2021236878B2 (en) 2025-09-11
EP4121003C0 (en) 2025-08-06
UA129439C2 (uk) 2025-04-23
AR121581A1 (es) 2022-06-15
RS67245B1 (sr) 2025-10-31
CN115279341A (zh) 2022-11-01
CN115279341B (zh) 2026-03-31
MX2022011227A (es) 2022-10-07
HUE073401T2 (hu) 2026-01-28
KR20220154110A (ko) 2022-11-21
US20250195424A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
CN104662038B (zh) 胰高血糖素类似物
JP5657230B2 (ja) Ｇｌｐ−１分子の投与方法
TWI459962B (zh) 包含胰島素、菸鹼醯胺及胺基酸的製劑
TWI468171B (zh) 含ｇｌｐ－１激動劑及甲硫胺酸之醫藥組成物
JP2005508360A (ja) Ｇｌｐ−１およびインスリンの二相混合物
CN102933598A (zh) 新型胰高血糖素类似物
US20250195424A1 (en) Liquid formulations of glucagon analogues
TWI880227B (zh) 澱粉素類似物之液體調配物
CN103328006A (zh) 包含胰岛素、烟酰胺和氨基酸的制剂
EP3649652A1 (en) Methods and medical uses relating to the treatment of hypoglycaemia
JP2025531387A (ja) Ｇｌｐ－１とｇｉｐの二重受容体アゴニスト医薬組成物及びその用途
RU2819934C1 (ru) Жидкие составы аналогов глюкагона
KR102956482B1 (ko) 글루카곤 유사체의 액체 제형
EA050539B1 (ru) Жидкие составы аналогов глюкагона
HK40078233A (en) Liquid formulations of glucagon analogues
HK40078233B (en) Liquid formulations of glucagon analogues
RU2838627C2 (ru) Жидкие композиции аналогов амилина
CA3268560A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260310

R150 Certificate of patent or registration of utility model

Ref document number: 7834025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150